Enjoy complimentary customisation on priority with our Enterprise License!
The montelukast sodium market size is forecast to increase by USD 1.34 billion at a CAGR of 4.5% between 2023 and 2028. Montelukast sodium, a leukotriene modifier, has been a popular treatment option for asthma and other noncommunicable diseases (NCDs), particularly chronic respiratory diseases. The market is witnessing significant growth due to the increasing demand for effective asthma medications. Furthermore, patient assistance initiatives by governments and advocacy groups are contributing to the expansion of this market. However, challenges persist in the form of complexities in screening and diagnosis, which hinder timely intervention and treatment. Montelukast sodium's dosage form, which is available in oral tablet and oral solution, offers convenience and flexibility for patients, making it a preferred choice for managing asthma symptoms. As the prevalence of asthma and other chronic respiratory diseases continues to rise, the market is expected to grow steadily, providing opportunities for stakeholders in the healthcare industry.
Montelukast sodium, a leukotriene inhibitor, has been a significant player in the healthcare industry for several years. This essential medication plays a crucial role in managing various chronic diseases, particularly asthma and allergies, which are among the most common noncommunicable diseases (NCDs) worldwide. Chronic diseases, including respiratory diseases, are a leading cause of morbidity and mortality, affecting millions of people worldwide. Asthma, a chronic inflammatory disorder of the airways, is one of the most common chronic diseases, affecting children and adults alike. Montelukast sodium is an essential component in the treatment of asthma, helping to reduce symptoms such as bronchospasm, wheezing, and shortness of breath. Montelukast sodium is available in different dosage forms, including tablets and oral solutions, making it convenient for patients to use. It is an essential medication for various respiratory maladies, including exercise-induced asthma, allergic rhinitis, and urticaria.
In addition, it has been effective in managing other chronic conditions such as pneumonia, COPD, and emphysema. The pediatric population is particularly vulnerable to respiratory diseases and allergies. Montelukast sodium has been approved for use in children, making it an essential medication for managing their symptoms. The patient epidemiology for asthma and allergies is significant, with millions of cases reported annually. Pipeline analysis shows that montelukast sodium continues to be a focus for research and development in the pharmaceutical industry. Its effectiveness in managing various respiratory diseases and allergies, as well as its convenience as a simple pill, makes it an attractive option for researchers. It works by inhibiting the action of leukotrienes, which are responsible for inflammation and bronchoconstriction in the airways.
In addition, it has also shown promise in managing fungal infections and allergic coryza. Despite the effectiveness of montelukast sodium, it is essential to note that it should not be used in emergency department settings for acute asthma exacerbations. Instead, it is most effective when used regularly as part of a long-term treatment plan. In conclusion, it plays a crucial role in managing various chronic respiratory diseases and allergies. Its effectiveness, convenience, and availability make it an essential medication for managing these conditions. With ongoing research and development, it is expected to continue to be a significant player in the healthcare industry.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD billion" for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.
The tablets segment is estimated to witness significant growth during the forecast period. Montelukast sodium tablets are a widely used dosage form for treating various noncommunicable diseases, particularly asthma and chronic respiratory diseases. These tablets are an essential component of oral medication, providing a cost-effective, safe, and efficient method for delivering essential active ingredients. The tablets are produced by compressing powdered substances into a hard, solid, smooth-coated pill that dissolves in the gastrointestinal tract.
Get a glance at the market share of various segments Download the PDF Sample
The tablets segment was valued at USD 2.26 billion in 2018. Additives are often included in tablets to enhance their properties, such as improving taste, texture, or appearance. Round, oblong, and disc-shaped tablets are available, with caplets being a type of oblong tablet designed for easier swallowing. Some tablets feature a scored line for easy splitting in half or a unique coating to prevent breakdown in the stomach. Montelukast sodium tablets play a crucial role in managing asthma and other chronic diseases, contributing significantly to the treatment of noncommunicable diseases worldwide.
For more insights on the market share of various regions Download PDF Sample now!
North America is estimated to contribute 38% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
The Montelukast Sodium market is experiencing significant growth due to the increasing prevalence of respiratory diseases, particularly asthma, in the pediatric population and the chronic nature of these conditions. Montelukast Sodium, available in oral solution dosage forms, plays a crucial role in managing symptoms and preventing exacerbations. In North America, this market is poised for substantial expansion due to several factors. Firstly, the presence of leading companies and a well-established healthcare infrastructure create a favorable business environment. Secondly, government initiatives and an increasing number of research collaborations are expected to accelerate market growth. The US, with its substantial patient population and developed healthcare market, holds the largest share in this region. The expanding patient pool, coupled with increasing disposable income, will contribute to the region's market growth during the forecast period.
Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The increasing demand for asthma medications is notably driving market growth. Asthma, a chronic respiratory condition, affects millions worldwide, causing breathing difficulties, bronchospasm, and airflow obstruction. The disease is aggravated by various factors, including air pollution and smoking. Montelukast sodium, a leukotriene inhibitor, is an essential medication used to alleviate asthma symptoms such as wheezing, chest tightness, and coughing in adults and children aged 12 months and above. The increasing global prevalence of asthma, with one in ten American children diagnosed with the condition according to the Environmental Protection Agency's August 2021 report, necessitates the use of effective treatments like montelukast sodium.
Moreover, montelukast sodium, marketed under the brand name Singulair, inhibits the effects of leukotrienes, potent inflammatory mediators, thereby reducing inflammation and bronchoconstriction. Moreover, montelukast sodium is beneficial in managing asthma symptoms in individuals with fungal infections and respiratory maladies. Its efficacy in treating asthma symptoms makes it an indispensable component of healthcare infrastructure. By managing asthma symptoms, montelukast sodium significantly improves patients' quality of life and reduces the risk of asthma exacerbations. Thus, such factors are driving the growth of the market during the forecast period.
The patient assistance initiatives by governments and advocacy groups is the key trend in the market. The geriatric population faces unique challenges when managing respiratory diseases such as COPD and asthma. These conditions carry a substantial economic burden, with the European Union and the United States reporting high direct costs. To alleviate the financial strain, various organizations have initiated funding programs. For instance, the Patient Access Network Foundation (PAN) has established a financial assistance fund, allowing eligible asthma patients to access specialty medications without financial hardship. Patients can receive up to USD 3,000 annually to cover medication costs.
However, drug consumption comes with potential adverse effects, including gastrointestinal discomfort and respiratory dysfunction. Retail pharmacies play a crucial role in ensuring proper medication usage and monitoring side effects. While the benefits of Montelukast Sodium are significant, it is essential to consider the carbon emissions generated during the manufacturing, transportation, and disposal processes. Therefore, it is crucial to explore sustainable production methods and responsible disposal practices to minimize the environmental impact. In conclusion, Montelukast Sodium plays a vital role in managing respiratory diseases for the geriatric population. However, addressing the economic burden, adverse effects, and environmental concerns requires a collaborative effort from all stakeholders, including healthcare providers, pharmacies, and regulatory bodies. Thus, such trends will shape the growth of the market during the forecast period.
The challenges associated with screening and diagnosis is the major challenge that affects the growth of the market. The prevalence of respiratory diseases, including pneumonia, emphysema, bronchospasm, allergic coryza, and others, remains a significant global health concern. Chronic respiratory diseases, such as pulmonary arterial hypertension (PAH), continue to rise due to challenges in screening and diagnosis. These conditions share non-specific symptoms, such as fatigue, weakness, and breathlessness, which can be easily mistaken for other common respiratory disorders like chronic obstructive pulmonary disease (COPD) or asthma. Montelukast sodium, available in simple pills, chewable pills, powder, and liquid solutions, has emerged as a potential solution for early diagnosis and treatment of respiratory diseases. Montelukast sodium is a leukotriene receptor antagonist that helps reduce inflammation and bronchoconstriction, making it an effective treatment for various respiratory conditions.
Its ease of administration and availability make it an attractive option for both patients and healthcare providers. Despite the challenges associated with diagnosing respiratory diseases, particularly PAH, the use of Montelukast sodium can help improve patient outcomes. By addressing the symptoms of respiratory diseases early and accurately, Montelukast sodium can help reduce the risk of complications and improve the overall quality of life for patients. In conclusion, the late diagnosis of respiratory diseases, including PAH, remains a significant challenge in healthcare. Montelukast sodium, with its ease of administration and effectiveness in treating various respiratory conditions, can help address this challenge and improve patient outcomes. Hence, the above factors will impede the growth of the market during the forecast period.
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Apotex Inc. - The company offers montelukast sodium tablets.
The market research and growth report also includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Montelukast sodium is a crucial medication used in the treatment of various noncommunicable diseases (NCDs), primarily focusing on asthma and other respiratory diseases. This leukotriene inhibitor plays a significant role in managing chronic conditions such as allergic rhinitis, urticaria, exercise-induced asthma, and bronchospasm. Montelukast sodium is available in different dosage forms, including tablets and oral solutions, catering to diverse patient needs. The pediatric population is a substantial consumer of montelukast sodium due to its efficacy in treating asthma and allergic rhinitis. The patient epidemiology for these conditions is substantial, with asthma affecting approximately 25 million Americans and allergic rhinitis affecting around 50 million. Pipeline analysis reveals ongoing clinical trials exploring montelukast sodium's potential in treating other respiratory diseases, such as pneumonia, emphysema, and allergic coryza. Healthcare providers rely on montelukast sodium as an alternative to inhaled corticosteroids (ICS) for managing respiratory diseases, especially in cases where ICS are not effective or appropriate. Montelukast sodium's usage extends beyond asthma and allergic rhinitis, with healthcare facilities employing it for treating various respiratory maladies.
Furthermore, factors contributing to the rising prevalence of these diseases include air pollution, smoking, and lifestyle changes. Montelukast sodium is available in simple pills, chewable pills, powder, and liquid solutions, catering to diverse patient preferences and requirements. The geriatric population also benefits from montelukast sodium, with health complications associated with aging increasing the demand for effective treatments. Despite its benefits, montelukast sodium, marketed as Singulair, is associated with adverse effects such as gastrointestinal discomfort and respiratory dysfunction. Patients should consult their healthcare providers for proper dosage and potential side effects. Montelukast sodium is available at retail pharmacies, with drug consumption influenced by factors such as carbon emissions and healthcare infrastructure.
Market Scope |
|
Report Coverage |
Details |
Page number |
140 |
Base year |
2023 |
Historic period |
2018-2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 4.5% |
Market growth 2024-2028 |
USD 1.34 billion |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
4.2 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 38% |
Key countries |
US, China, Canada, Germany, and UK |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
Apotex Inc., Aurobindo Pharma Ltd., Bio Techne Corp., Cayman Chemical Co, Cipla Inc., Glenmark Pharmaceuticals Ltd., Hetero Healthcare Ltd., Hikma Pharmaceuticals Plc, Jubilant Pharmova Ltd., Krosyl Pharmaceuticals Pvt. Ltd., Merck and Co. Inc., Morepen Laboratories Ltd., Novartis AG, Simson Pharma Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Unichem Laboratories Ltd., Unimark Remedies Ltd., and Viatris Inc. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the market forecast period |
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Type
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Opportunity/Restraints
10 Competitive Landscape
11 Competitive Analysis
12 Appendix
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.